Skip to main content

For chronic weight management in adult patients with a BMI ≥30 kg/m2, or ≥27 kg/m2 with one or more weight-related comorbidities, as an adjunct to a reduced-calorie diet and increased physical activity. Click for Limitations of Use.

Additional Weight Loss

In a clinical study, patients continued to lose weight once adding Saxenda® to a low-calorie diet and physical activity.1,2

Additional Weight Loss

In a clinical study, patients continued to lose weight once adding Saxenda® to a low-calorie diet and physical activity.1,2

Actor Portrayal.

Mean Weight Loss From Start of Run-in Period to End of Trial

After reaching clinically meaningful weight loss through a low-calorie diet and physical activity alone

Patients adding Saxenda® achieved double-digit mean weight loss of 12.8%2

In a 56-week study of 422 patients without type 2 diabetes and with a BMI ≥30, or ≥27 with at least 1 weight-related comorbidity, patients were randomized after a run-in period to either Saxenda® (n=212) or placebo (n=210), and all patients received counseling on caloric intake and physical activity.1,2

 

Graph depicting additional weight loss results from a Saxenda® clinical trial
Graph depicting additional weight loss results from a Saxenda® clinical trial
Graph depicting additional weight loss results from a Saxenda® clinical trial
  • Intention to treat with weighted-average data show a mean weight loss of 4.9% for patients on Saxenda® (n=177) vs a mean weight gain of 0.3% for patients on placebo (n=169) (P<0.0001). Therefore, adding Saxenda® after initial 6.0% mean weight loss during the run-in period resulted in a double-digit weight loss of 10.9%2

Intention to treat with weighted-average data show a mean weight loss of 4.9% for patients on Saxenda® (n=177) vs a mean weight gain of 0.3% for patients on placebo (n=169) (P<0.0001). Therefore, adding Saxenda® after initial 6.0% mean weight loss during the run-in period resulted in a double-digit weight loss of 10.9%2

  • Because losing ≥5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in period was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population1

Because losing ≥5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in period was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population1
 

At randomization, mean baseline body weight was 219.1 lb, and mean BMI was 35.6 kg/m2  

  • At randomization, mean baseline body weight was 219.1 lb, and mean BMI was 35.6 kg/m2  

Maintained Weight Loss

After reaching clinically meaningful weight loss through a low-calorie diet and physical activity alone

81% of patients maintained clinically meaningful weight loss with Saxenda®2

Percentage of patients at 56 weeks who maintained ≥5% mean weight loss achieved in run-in period2

Graph depicting sustained weight loss results from a Saxenda® clinical trial
Graph depicting sustained weight loss results from a Saxenda® clinical trial
Graph depicting sustained weight loss results from a Saxenda® clinical trial
Click below to expand
  • Results from a 56-week, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Saxenda®
  • Patients with a BMI ≥30, or ≥27 with 1 or more weight-related comorbidities (N=422) were randomized to receive once-daily Saxenda® (n=212) or placebo (n=210) in conjunction with a lifestyle modification program that included increased physical activity and a 500-kcal/day-deficit diet 
  • Patients were first treated with a low-calorie diet (total energy intake: 1,200-1,400 kcal/day) and with increased physical activity in the run-in period lasting up to 12 weeks. Patients who lost at least 5% of screening body weight during the run-in period were randomized, then underwent a 4-week dose-escalation period followed by 52 weeks on the full dose
  • The primary end points were mean percent weight change from randomization to week 56, percentage of patients not gaining more than 0.5% body weight from randomization to week 56, and percentage of patients achieving ≥5% weight loss from randomization to week 56
  • Mean baseline body weight was 219.1 lb and mean BMI was 35.6 kg/m
  • Patients with type 2 diabetes were excluded from participating
Saxenda® Pen

Complimentary samples of Saxenda® are available

Complimentary samples of Saxenda® are available

RECOMMENDED CONTENT

Sustained Weight Loss

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

Indications and Usage

  • Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use

  • Saxenda® is not indicated for the treatment of type 2 diabetes 
  • Saxenda® and Victoza® both contain the same active ingredient, liraglutide, and therefore should not be used together. Saxenda® should not be used in combination with any other GLP-1 receptor agonist 
  • Saxenda® has not been studied in patients taking insulin. Saxenda® and insulin should not be used together 
  • The safety and efficacy of Saxenda® in combination with other products for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established

Important Safety Information

Contraindications

Saxenda® is contraindicated in:

  • Patients with a personal or family history of MTC or MEN 2 
  • Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the product components 
  • Pregnancy

Warnings and Precautions

  • Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated 
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Saxenda® promptly and if pancreatitis is confirmed, do not restart 
  • Acute Gallbladder Disease: Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated 
  • Risk of Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy: When Saxenda® is used with an insulin secretagogue (eg, a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia. Monitor blood glucose parameters prior to starting Saxenda® and during treatment and adjust anti-diabetic drugs as needed 
  • Heart Rate Increase: Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed in patients treated with Saxenda®. Monitor heart rate at regular intervals and inform patients to report palpitations or feelings of a racing heartbeat while at rest during treatment with Saxenda®. Discontinue Saxenda® in patients who experience a sustained increase in resting heart rate 
  • Renal Impairment: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment 
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported in patients treated with liraglutide. If a hypersensitivity reaction occurs, patients should stop taking Saxenda® and promptly seek medical advice 
  • Suicidal Behavior and Ideation: In clinical trials, 9 (0.3%) of 3,384 patients treated with Saxenda® and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the patients treated with Saxenda® attempted suicide. Monitor patients on Saxenda® for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment if patients experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation

Adverse Events

  • The most common adverse reactions, reported in ≥5% are: nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase

Drug Interactions

  • Saxenda® causes a delay of gastric emptying, and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®

Use in Specific Populations

  • There are no data on the presence of liraglutide in human breast milk; liraglutide was present in the milk of lactating rats 
  • Saxenda® has not been studied in patients below 18 years of age and is not recommended for use in pediatric patients 
  • Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis

Please click here for Prescribing Information, including Boxed Warning.

 

Click below to expand

1. Saxenda® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2018.

2. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111-2120.